HeraMED (ASX:HMD) has raised US$2.8 million via placement and SPP
June 2020 — HeraMED Limited (ASX:HMD) has raised funds to accelerate HearCARE’s commercial roll out and progress ongoing research projects.
HeraMED is a medical technology company leading the digital transformation of maternity care with its proprietary telehealth platform. The company offers a platform that utilizes hardware and software to reshape the doctor/patient relationship using its clinically validated in-home fetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, big data and a digital social networking dashboard.
Our role in the transaction
Oaklins’ team in Australia acted as lead manager in this transaction.
Talk to the deal team
Related deals
OEP Danzig BidCo has completed a mandatory tender offer for the shares of Digital Value
OEP Danzig BidCo S.p.A. has completed a mandatory tender offer for the shares of Digital Value S.p.A.
Learn moreBolster Investment Partners has secured debt financing for the acquisition of Royal Taste Company
Bolster Investment Partners has partnered with Royal Taste Company, a leading Dutch custom signature coffee platform offering end-to-end sourcing, blending, roasting, packaging and delivery services. The partnership marks an important next step in Royal Taste Company’s growth trajectory, focused on further geographical expansion, commercial development and selective strategic acquisitions.
Learn moreIndigo Capital has acquired a minority stake in Vivason
Indigo Capital has acquired a minority stake in Vivason, a leading network of hearing care centers, to support the company’s growth and enable management to increase its ownership stake.
Learn more